On Tuesday, Bioventus Inc. BVS reported fourth-quarter adjusted EPS of 15 cents, up from 7 cents, beating the consensus of 8 cents.

The medical device company reported sales of $153.6 million, up 13.5% year over year, beating the consensus of $145.2 million, driven by double-digit growth in pain treatments and surgical solutions.

Pain treatment sales increased 18.7% to $62.8 million, Surgical Solutions sales increased 16.8% to $46.43 million and Restorative Therapies sales fell marginally by 0.6% to $25.95 million.

Net loss from continuing operations was $0.3 million, compared to $7.7 million a year ago. Adjusted EBITDA from continuing operations of $28.3 million advanced 28.3% from $22.0 million last year due to strong revenue growth and adjusted gross margin expansion.

Also Read: Ferguson Stock Drops As Q2 EPS Miss, Margin Squeeze Overshadow Sales Growth

In the fourth quarter, the company strengthened its balance sheet and improved liquidity by reducing long-term debt by $48.3 million.

Guidance: Bioventus expects 2025 sales of $560 million—$570 million versus a consensus of $554.62 million, reflecting an organic growth of approximately 6.1% to 8.0% when including the impact of the company’s divestiture of its Advanced Rehabilitation Business, which generated revenue of $45.4 million in 2024.

The company expects 2025 adjusted EPS of $0.64-$0.68 compared to Street estimates of $0.55.

Adjusted EBITDA is expected to be $112 million to $116 million, reflecting 100 basis points in Adjusted EBITDA Margin growth compared to the 2024 and EBITDA margin of 19.0% when using the low end of the 2025 revenue and adjusted EBITDA guidance.

Price Action: BVS stock is up 21.9% at $10.68 at the last check Tuesday.

Read Next:

• Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal

Photo: Shutterstock